Home・Aktien・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Geschlossen

3.7 4.82

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.51

Max

3.84

Schlüsselkennzahlen
By Trading Economics
Einkommen	-42M -78M
EPS	-0.59
Angestellte	106
EBITDA	-42M -77M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+148.03% upside

Dividenden
By Acuity
Nächstes Ergebnis	6. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-34M 297M
Vorheriger Eröffnungskurs	-1.12
Vorheriger Schlusskurs	3.7

Zentalis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Aug. 2026, 23:57 UTC

Ambarella shares declined during after-market hours amid broader geopolitical concerns affecting market sentiment. The stock remained above its 20-day moving average.

17. Aug. 2026, 23:56 UTC

Correlated Moves

Energy Fuels Inc. shares rose in after-market trading amid positive sentiment in the energy sector and rising crude oil prices due to geopolitical tensions.

17. Aug. 2026, 23:56 UTC

Insteel Industries Inc shares are lower in after-market hours, following a slight decline after Monday's close amid broader market geopolitical concerns.

17. Aug. 2026, 23:56 UTC

Correlated Moves

Valley National Bancorp shares are trading higher in after-market hours, reflecting stability as they remain near the upper end of their one-month range.

17. Aug. 2026, 23:56 UTC

Shares of Aquestive Therapeutics Inc. are trading higher in after-market hours, remaining significantly above their 20-day moving average. No specific news was identified.

17. Aug. 2026, 23:56 UTC

Social Media

Immunovant shares are higher in after-market trading, driven by positive sentiment around the product pipeline for IMVT-1402 and comparisons to ARGX's success.

17. Aug. 2026, 23:56 UTC

Geron Corp shares are higher in after-market trading, reflecting notable strength. The stock is significantly above its 20-day moving average.

17. Aug. 2026, 23:56 UTC

Brown & Brown Inc. shares are trading lower in after-market hours, continuing a trend of three consecutive sessions finishing lower and remaining below the 20-day moving average.

17. Aug. 2026, 23:56 UTC

iHeartMedia Inc shares are higher in after-market trading, recovering from earlier declines amid geopolitical concerns and rising crude oil prices.

17. Aug. 2026, 23:56 UTC

Clean Harbors Inc. shares are higher in after-market trading, reflecting a modest gain since Monday's close amid rising crude oil prices and geopolitical tensions.

17. Aug. 2026, 23:56 UTC

ETF Constituents

Correlated Moves

Macro News

Boston Properties announced a $700 million public offering of senior unsecured notes due in 2036, funding existing debt repayment. VNQ remains roughly flat in after-market trading.

17. Aug. 2026, 23:56 UTC

Mondelez International Inc. is seeing modest gains in after-market trading. Broader market dynamics have influenced trading activity today, but no specific news was identified.

17. Aug. 2026, 23:56 UTC

Correlated Moves

Eastman Chemical Co shares are lower in after-market hours amid market volatility and rising crude oil prices, influenced by geopolitical tensions in the Middle East.

17. Aug. 2026, 23:56 UTC

Oil States International shares rise in after-market hours, supported by increasing Brent crude prices, which reached $90.68 amid Middle East geopolitical tensions.

17. Aug. 2026, 23:56 UTC

Sabre Corp shares are lower in after-market trading, amid notable volatility and broader market concerns over escalating geopolitical tensions and rising crude oil prices.

17. Aug. 2026, 23:56 UTC

Correlated Moves

Northern Oil and Gas Inc remains roughly flat in after-market trading amid geopolitical concerns affecting oil prices, which saw a slight uptick.

17. Aug. 2026, 23:56 UTC

News

Social Media

Axon Enterprise shares are lower in after-market hours, following a report highlighting high valuations and recent military contracts from Bulgaria.

17. Aug. 2026, 23:56 UTC

Accuray Inc shares are lower in after-market trading amid broader market fluctuations and geopolitical concerns, though they remain above their 20-day moving average.

17. Aug. 2026, 23:56 UTC

United Airlines shares advanced in after-market trading, reflecting a modest rise despite geopolitical concerns and rising crude oil prices impacting operational costs.

17. Aug. 2026, 23:56 UTC

Correlated Moves

Flowers Foods Inc remains roughly flat in after-market trading amid broader market movements influenced by escalating geopolitical tensions in the Middle East.

17. Aug. 2026, 23:56 UTC

Transocean Ltd shares are higher in after-market trading, supported by rising crude oil prices amid geopolitical tensions affecting shipping routes.

17. Aug. 2026, 23:56 UTC

News

Warner Bros Discovery shares are lower in after-market trading amid ongoing litigation over its merger with Paramount, which faces a $1.9 billion bond request.

17. Aug. 2026, 23:56 UTC

News

Allstate Corp shares are lower in after-market hours amid broader market weakness. Geopolitical concerns are affecting trading sentiment despite recent positive earnings highlights.

17. Aug. 2026, 23:56 UTC

Williams Companies shares are higher in after-market trading, supported by rising crude oil prices amid geopolitical tensions in the Middle East.

17. Aug. 2026, 23:56 UTC

News

Replimune Group Inc shares are lower in after-market hours amid negative sentiment from multiple class action lawsuits alleging securities fraud and misleading statements.

17. Aug. 2026, 23:56 UTC

Albany International shares declined in after-market hours amid broader market weakness. The stock remains below its 20-day moving average and near its one-month low.

17. Aug. 2026, 23:56 UTC

Array Technologies shares are higher in after-market hours, despite trading below their 20-day moving average amid broader market dynamics and geopolitical tensions.

17. Aug. 2026, 23:56 UTC

Correlated Moves

Macro News

Crude oil prices increased amid escalating tensions in the Middle East, influencing broader market volatility. The US 30Y Treasury Bond Index is trading slightly higher.

17. Aug. 2026, 23:52 UTC

Fifth Third Bancorp shares are lower in after-market trading amid rising geopolitical tensions and increasing crude oil prices, with no specific company news identified.

17. Aug. 2026, 23:52 UTC

Australia's Consumer Confidence Data Release Set for August 18 Amidst Fragile Economic Sentiment and High Inflation Concerns.

Peer-Vergleich

Kursveränderung

Zentalis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

148.03% Vorteil

12-Monats-Prognose

Durchschnitt 8.83 USD 148.03%

Hoch 11 USD

Tief 5 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zentalis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Zentalis Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.